ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.
Externer Link zu ARTBIO
Cambridge, Massachusetts, US
Oslo, NO
Basel, CH
London, GB
ARTBIO hat dies direkt geteilt
The group I'm in at ARTBIO is growing! We are looking for a biochemist/biophysicist with some plate based assay experience (SPR or ITC experience are a plus)! Reach out if you're interested or know someone that might be a good fit! https://lnkd.in/ePUZqZVk
We are delighted to announce that ARTBIO has entered into a master supply agreement with Thor Medical ASA. Thor Medical will supply #thorium (Th-228) to ARTBIO for the manufacturing of Pb212 through our proprietary AlphaDirect technology to support the development of our pipeline of novel #Alpha #Radioligand #Therapies. Learn more: https://shorturl.at/l9GXl Thor Medical is pioneering methods to recover Th228 from existing material stockpiles rather than manufacturing it by irradiating other materials. We look forward to working closely with them in our Oslo laboratories, not far away from their production site. #NuclearMedicine #RadioligandTherapy #Radiopharmaceuticals #Biotech #ProstateCancer #ARTs
Thor Medical signs first supply agreement as key building block to commercial scale production📝🌟 Today marks a significant step forward in enabling next-generation cancer therapies with the announcement of the strategic long-term supply agreement of Thorium-228 to ARTBIO: ◾ 5-years of supply agreement, representing revenues for Thor Medical of up to NOK 200 million over the term ◾ Potential to increase deliveries and revenues up to NOK 400 million, conditional on certain milestones including production ramp-up and market development "Securing strategic supply agreements are an important prerequisite for a positive investment decision for our planned commercial production plant. The agreement with ARTBIO represents significant progress in the efforts to commercialize large-scale production and supply of the world's purest radionuclides from the natural decay of thorium to help transform cancer care", says Jasper C. Kurth, CEO of Thor Medical. The Thorium-228 will be produced at the planned commercial-scale facility at Herøya Industripark AS, where Thor Medical expects to make the final investment decision in Q1 2025. The company assumed pilot production at the same site earlier this month. “A stable and reliable supply of high-quality isotopes is key to the successful development of our pipeline and partnering with Thor Medical is a valuable next step in building out the supply chain that supports our pipeline of novel alpha radioligand therapies, including our lead asset AB001 for the treatment of prostate cancer”, says Emanuele Ostuni, CEO of ARTBIO. Check out the full release 👉 https://lnkd.in/d_D5iZmx #alphaemitters #alpharadioligandtherapies #art #precisioncancertreatment
The European Association of Nuclear Medicine (EANM) Annual Congress kicks off this Saturday and we’re thrilled to be attending! Join us as we explore the latest advancements in #NuclearMedicine, share insights with industry leaders, and connect with fellow innovators. Together, we can shape the future of patient care and drive meaningful change in the field. Stay tuned for updates from the event! #EANM24 #RadioligandTherapy #Radiopharmaceuticals #Biotech Emanuele Ostuni | Conrad Wüller | ✪ Philippe Dasse ✪ ☤ | Daniel Rossetto | Phil Ruis | Vicki Jardine | Ivana Galetic | Mohana Suppiah-Coll | Tanja Aarvak | Elisa Fiorito, Ph.D. | Vilde Yuli Stenberg | Joshua Needham-Clark | Rosa Greasley | Jordi Vall-llossera
Please join us in welcoming Amra Demirovic as Chief Human Resources Officer! Amra brings extensive experience in human resources and a proven track record of fostering inclusive workplace cultures. Amra comes to us from BeiGene, where she led HR for Europe & New Markets. Prior to that, she held key HR positions at Novartis. Amra loves sports and exploring the world with her son. Welcome to the team, Amra! #nuclearmedicine #radioligandtherapy #radiopharmaceuticals #biotech #team
ARTBIO hat dies direkt geteilt
ARTBIO is looking for a Radiobiology Scientist in Oslo! This is an exciting opportunity to work with a fantastic team on radioligand therapies for cancer. #radiobiology #radioligandtherapy #hiring #workinbiotech #drugdiscovery
We are delighted to welcome Phanindra Prakash, CPA, ACMA, CTM as ARTBIO’s new Director of Financial Planning & Analysis! With over 12 years of experience in various finance roles within the pharmaceutical industry, Phanindra brings rich expertise in treasury, financial planning, and reporting to our team. Phanindra’s financial background paired with his experience working across cross-functional and cultural environments will be instrumental in supporting ARTBIO’s growth as we advance our differentiated #ART pipeline. We look forward to working with Phanindra! #nuclearmedicine #radioligandtherapy #radiopharmaceuticals #biotech #team
ARTBIO hat dies direkt geteilt
Great opportunity for a peptide chemists to work with our growing team in Cambridge. https://lnkd.in/eGN-cJdK
In honor of #WorldCancerResearchDay, we shine a light on the remarkable efforts of our ARTBIO team, dedicated to redefining cancer care through #alpha #radioligand #therapy. Our commitment to innovation and patients drives us forward as we harness the power of #ARTs to set new standards in #nuclearmedicine. Join us in recognizing everyone who does their part, making a lasting impact in the fight to overcome cancer. Learn more about our novel approach at www.artbio.com #nuclearmedicine #biotech
ARTBIO hat dies direkt geteilt
#NewMembers | An enthusiastic welcome to ARTBIO as the newest member of our Pharma.Aero's global network of life science and pharmaceutical industry leaders, the Life Science Manufacturers Advisory Board (LMAP)! We look forward to working closely together to drive innovation, enhance supply chain efficiency, and bring transformative solutions to the pharmaceutical logistics landscape. ARTBIO is a clinical-stage #radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). ARTBIO is deeply rooted in a long-standing scientific legacy of pioneering work in #radiation_therapy, originating from groundbreaking research conducted at the University of Oslo and The Norwegian Radium Hospital. This renowned research hub, with a lineage tracing back to Marie Curie, has been instrumental in advancing the field of radiology. https://lnkd.in/dJRGfhKE Excited for the impactful collaborations ahead! Daniel Rossetto | Conrad Wüller | Trevor Caswell | Zhong Yao Liew | Gergely Szorcsik | Roland Yap EdD MEMDT MBCC EMLSI MPPM MEd MA | Samuel Speltdoorn | Hugo Repolho | Bruno Guella | Frank Van Gelder #LifeScience #PharmaLogistics #Collaboration
#ProstateCancer remains one of the most prevalent cancers among men globally, with roughly 1 in 44 men losing their lives to this disease. In recognition of National #ProstateCancerAwarenessMonth, ARTBIO is bringing attention to the importance of regular screenings and the urgent need for innovative therapies. Hundreds of thousands of new cases arise each year, and for those diagnosed with prostate cancer, there's a significant need for therapies that not only target tumors with greater precision and efficacy but also prioritize patient safety and comfort. At ARTBIO, we're redefining cancer care with our innovative #alpha #radioligand #therapies. Through our lead program, AB001, we aim to address the unmet need for more effective and safer therapeutic options for prostate cancer, bringing us closer to realizing the full potential of #radioligandtherapy. Learn more about our mission at www.artbio.com #ART #nuclearmedicine #biotech #RLT #radiopharmaceuticals